Contact Kay Kelley, RN for more information
1. Tissue and blood Library establishment for Molecular, Biochemical and Histologic Study of Breast disease
2. Creation of a Blood Library for the Analysis of Blood for Molecular Changes Associated with Breast Disease and Breast Cancer Development
3. Molecular Phenotyping of Bone Marrow Aspirates and Peripheral Blood Collected as Part of the Walter Reed Army Medical Center Clinical Breast Care Project (CBCP)
3. Electrical Impedance Scanning for the Early Detection of Breast Cancer in Young Women
4. Adriamycin/Cyclophosphamide (4 vs 6 cycles) vs patcytaxol (4 vs 6 cycles) in breast cancer patients with zero to 3 positive lymph nodes
5. Vaccine trial - for prophylaxis of recurrance "Following primary treatment completion for all stages of breast cancer"
6. Adjuvent therapy following surgery and radiation : CTSU: SOFT Ovarian Function Suppression (OFS) + exemestane vs tamoxifen or OFS + exemestane vs OFS + tamoxifen
7. Premenuposal breast cancer patients : CTSU: TEXT Ovarian Function Suppression (OFS) + tamoxifen vs OFS + exemestane in premenopausal women +/- chemotherapy
8. CTSU Adrimoycin / cyclophsomide weekly vs every 2 weeks, followed by pacliTaxol weekly or every 2 weeks in Node-Positive or High-Risk Node Negative (4 arm study)
9. CTSU: Anastrozole vs Fulvestrant as first line therapy for post menopausal women with metastatic breast cancer
10. Randomized study of adjuvant chemotherapy for radically resected Local-regional relapse of breast cancer
11. Adjuvant cytotoxic therapy in addition to hormonal therapy in Estrogen Receptor Positve and or Projestorone Receptor Postive breast cancer patient with negative axillary lymph nodes.
12. Chemotherapy decisions & outcomes in elderly women with breast cancer
National Capital Area Clinical Trials
USMCI provides summary and contact information about federally and
privately supported clinical research in human volunteers in the
military National Capital Area. For more information on the trials, please contact the indicated Investigator listed below the summary.
INVESTIGATOR NOTE: Investigators wishing to register trials should refer to the WRAMC DCI WARP system.
Breast Cancer
Colon or Gastric Cancer
Contact Kay Kelley, RN for more information
1. Biological Relevance of Sentinel Lymph Node Micrometastasis in Patients with Colon Carcinoma.
2. Metastatic colon cancer (FOLFOX/FOLFIRI + bv, + C225, or + bv/C225 for mets colon ca)
3. Adjuvant chemotherapy after resection of gastric adenocarcinoma
1. Biological Relevance of Sentinel Lymph Node Micrometastasis in Patients with Colon Carcinoma.
2. Metastatic colon cancer (FOLFOX/FOLFIRI + bv, + C225, or + bv/C225 for mets colon ca)
3. Adjuvant chemotherapy after resection of gastric adenocarcinoma
Gynecologic Oncology
Contact Dr Chernofsky for more information
1. GOG209 Randomized Phase III Trial of Doxorubicin/Cisplatin/Paclitaxel and G-CSF versus Carboplatin/Paclitaxel in Patients with Stage III, IV or Recurrent Endometrial Cancer
2. GOG218 A Phase III trial of Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cancer
3. GOG212 A Randomized Phase III Trial of Maintenance Chemotherapy Comparing 12 Monthly Cycles of Single Agent Paclitaxel, Xyotax (CT 2103) (IND#61013), Versus No Treatment Until Documented Relapse in Women with Advanced Ovarian or Primary Peritoneal Cancer who Achieve a Complete Clinical Response to Primary Platinum/Taxane Chemotherapy
4. Acquisition of Human Gynecologic Tissue Specimens and Serum to be used in Studying the Causes, Diagnosis, Prevention and Treatment of Cancer
5. Tissue and Data Acquisition Activity for the Study of Gynecologic Disease
6. The Chemoprotective Effects of Progestin on the Endometrial Lining
7. Phase Ib Trial of HER2/neu Peptide (E75) Vaccine in Ovarian and Endometrial Cancer Patients
8. Phase 1b Trial of Folate Binding Protein (FBP) Peptide (E39) Vaccine in Ovarian and Endometrial Cancer Patients
9. Gynecologic Cancer Survivorship Survey
10. Outcomes from Fibroid Therapies: A Comparison with Normal Controls
1. GOG209 Randomized Phase III Trial of Doxorubicin/Cisplatin/Paclitaxel and G-CSF versus Carboplatin/Paclitaxel in Patients with Stage III, IV or Recurrent Endometrial Cancer
2. GOG218 A Phase III trial of Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cancer
3. GOG212 A Randomized Phase III Trial of Maintenance Chemotherapy Comparing 12 Monthly Cycles of Single Agent Paclitaxel, Xyotax (CT 2103) (IND#61013), Versus No Treatment Until Documented Relapse in Women with Advanced Ovarian or Primary Peritoneal Cancer who Achieve a Complete Clinical Response to Primary Platinum/Taxane Chemotherapy
4. Acquisition of Human Gynecologic Tissue Specimens and Serum to be used in Studying the Causes, Diagnosis, Prevention and Treatment of Cancer
5. Tissue and Data Acquisition Activity for the Study of Gynecologic Disease
6. The Chemoprotective Effects of Progestin on the Endometrial Lining
7. Phase Ib Trial of HER2/neu Peptide (E75) Vaccine in Ovarian and Endometrial Cancer Patients
8. Phase 1b Trial of Folate Binding Protein (FBP) Peptide (E39) Vaccine in Ovarian and Endometrial Cancer Patients
9. Gynecologic Cancer Survivorship Survey
10. Outcomes from Fibroid Therapies: A Comparison with Normal Controls
Leukemia
Contact Dr TBD for more information
1. Molecular markers of Chronic Lymphocytic Leukemia-companion study
2. CC5013 for prevention of disease progression after Autologous Stem Cell Transplant
3. Use of AMD3100 to mobilize peripheral blood stem cells for collection and transplantation
4. Examination of Paroxysmal Nocturnal Hemoglobinuria, by Level Of CD59 on REd and white blood cells, in bone marrow failure syndromes
1. Molecular markers of Chronic Lymphocytic Leukemia-companion study
2. CC5013 for prevention of disease progression after Autologous Stem Cell Transplant
3. Use of AMD3100 to mobilize peripheral blood stem cells for collection and transplantation
4. Examination of Paroxysmal Nocturnal Hemoglobinuria, by Level Of CD59 on REd and white blood cells, in bone marrow failure syndromes
Lymphoma
Contact Dr TBD for more information
1. Non Hotchkins Lymphoma: R-CHOP vs EPOCH-R in Diffuse Large B-cell Lymphoma
2. Anti-cd30 antibody, sgn-30, in combination with Gemcitabine, Vinorelbine, and Peglated Liposomal Doxorubicin (GVD) for patients with relapsed/refractory Hodgkin's Lymphoma
3. Comparing two different Rituximab dosing regimens for patients with low tumor burden indolent non-Hodgkin lymphoma
1. Non Hotchkins Lymphoma: R-CHOP vs EPOCH-R in Diffuse Large B-cell Lymphoma
2. Anti-cd30 antibody, sgn-30, in combination with Gemcitabine, Vinorelbine, and Peglated Liposomal Doxorubicin (GVD) for patients with relapsed/refractory Hodgkin's Lymphoma
3. Comparing two different Rituximab dosing regimens for patients with low tumor burden indolent non-Hodgkin lymphoma
Pediatric - Hematology Oncology
Contact Wanda Salzer for more information
1. ANBL00B1 Neuroblastoma Biology Studies
2. AALL0232 High Risk B-Precursor Acute Lymphoblastic Leukemia
3. AALL03B1 Classification of Acute Lymphoblastic Leukemia
4. AAML0531 A Phase III Randomized Trial of Gemtuzumab Ozogamicin (Mylotarg) Combined with Conventional Chemotherapy for De Novo Acute Myeloid Leukemia (AML) in Children, Adolescents, and Young Adults
5. AHOD0031 A Phase III Group-wide Study of Dose-intensive Response-based Chemotherapy and Radiation Therapy for Children and Adolescents with Newly Diagnosed Intermediate Risk Hodgkin Disease
6. AHOD0431 A Phase III Study for the Treatment of Children and Adolescents with Newly Diagnosed Low Risk Hodgkin Disease
7. AALL0331 Standard Risk B-Precursor Acute Lymphoblastic Leukemia: A Phase III Group-wide Study
8. Use of Erwinia Asparaginase Following Allergy to PEG-Asparaginase in Treatment of Children with Acute Lymphoblastic Leukemia – WU #07-66011)
9. AREN03B2 Renal Tumors Classification, Biology, and Banking Study
10. AREN0321 Treatment of High Risk Renal Tumors
11. AALL0434 Intensified Methotrexate, Nelarabine (Compound 506U78; IND # 52611) and Augmented BFM Therapy for Children and Young Adults with Newly Diagnosed T-cell Acute Lymphoblastic Leukemia
1. ANBL00B1 Neuroblastoma Biology Studies
2. AALL0232 High Risk B-Precursor Acute Lymphoblastic Leukemia
3. AALL03B1 Classification of Acute Lymphoblastic Leukemia
4. AAML0531 A Phase III Randomized Trial of Gemtuzumab Ozogamicin (Mylotarg) Combined with Conventional Chemotherapy for De Novo Acute Myeloid Leukemia (AML) in Children, Adolescents, and Young Adults
5. AHOD0031 A Phase III Group-wide Study of Dose-intensive Response-based Chemotherapy and Radiation Therapy for Children and Adolescents with Newly Diagnosed Intermediate Risk Hodgkin Disease
6. AHOD0431 A Phase III Study for the Treatment of Children and Adolescents with Newly Diagnosed Low Risk Hodgkin Disease
7. AALL0331 Standard Risk B-Precursor Acute Lymphoblastic Leukemia: A Phase III Group-wide Study
8. Use of Erwinia Asparaginase Following Allergy to PEG-Asparaginase in Treatment of Children with Acute Lymphoblastic Leukemia – WU #07-66011)
9. AREN03B2 Renal Tumors Classification, Biology, and Banking Study
10. AREN0321 Treatment of High Risk Renal Tumors
11. AALL0434 Intensified Methotrexate, Nelarabine (Compound 506U78; IND # 52611) and Augmented BFM Therapy for Children and Young Adults with Newly Diagnosed T-cell Acute Lymphoblastic Leukemia
Prostate Cancer
Contact Stephen A. Brassell, MD for more information
1. High Risk Prostate Cancer (Dana Farber) - Initial treatment of high risk prostate cancer using radiation and hormones with addition of chemotherapy.
2. High Risk Prostate Cancer (CALGB 90203) - Initial treatment of high risk prostate cancer using surgery and hormones with addition of chemotherapy.
3. Erectile Function (Viagra)- Novel use of Viagra in the post-operative setting in an attempt to improve recovery of erectile function.
4. High Intensity Focused Ultrasound (HIFU) - Salvage treatment of recurrent prostate cancer after radiation (brachytherapy or external beam) using a non-invasive technique.
5. Recurrent prostate cancer (Sanofi/Encorium)- Treatment of recurrent prostate cancer after surgery with hormones and chemotherapy.
6. Recurrent prostate cancer (Theralogix) - Treatment of recurrent prostate cancer after any primary treatment with a novel nutritional supplement.
7. Hormone refractory prostate cancer (TARP) - Treatment of recurrent prostate cancer that has failed initial hormonal deprivation with a novel combination of hormonal therapies.
8. Hormone refractory prostate cancer (BNIT Vaccine) - Treatment of recurrent prostate cancer that has failed initial hormonal deprivation with a novel vaccine.
9. Hormone refractory prostate cancer (AZ 14,15,33) - Treatment of recurrent prostate cancer that has failed initial hormonal deprivation with a novel oral medication (ZD 4050).
10. Decision Making and Quality of Life Study - Newly diagnosed patients with prostate cancer are eligible to participate in order to further understand how treatment decisions are made and how those decisions effect quality of life.
1. High Risk Prostate Cancer (Dana Farber) - Initial treatment of high risk prostate cancer using radiation and hormones with addition of chemotherapy.
2. High Risk Prostate Cancer (CALGB 90203) - Initial treatment of high risk prostate cancer using surgery and hormones with addition of chemotherapy.
3. Erectile Function (Viagra)- Novel use of Viagra in the post-operative setting in an attempt to improve recovery of erectile function.
4. High Intensity Focused Ultrasound (HIFU) - Salvage treatment of recurrent prostate cancer after radiation (brachytherapy or external beam) using a non-invasive technique.
5. Recurrent prostate cancer (Sanofi/Encorium)- Treatment of recurrent prostate cancer after surgery with hormones and chemotherapy.
6. Recurrent prostate cancer (Theralogix) - Treatment of recurrent prostate cancer after any primary treatment with a novel nutritional supplement.
7. Hormone refractory prostate cancer (TARP) - Treatment of recurrent prostate cancer that has failed initial hormonal deprivation with a novel combination of hormonal therapies.
8. Hormone refractory prostate cancer (BNIT Vaccine) - Treatment of recurrent prostate cancer that has failed initial hormonal deprivation with a novel vaccine.
9. Hormone refractory prostate cancer (AZ 14,15,33) - Treatment of recurrent prostate cancer that has failed initial hormonal deprivation with a novel oral medication (ZD 4050).
10. Decision Making and Quality of Life Study - Newly diagnosed patients with prostate cancer are eligible to participate in order to further understand how treatment decisions are made and how those decisions effect quality of life.